Saturday, 31 October 2026European Markets

SAINT JEAN GROUPE Stock Impressive Fall 10% So Far On Tuesday, Underperforms Market

Loading stream...

saint jean groupe's (cac 40: sabe.pa) shares experienced an extreme drop of 10.45% to eur19.70 after two consecutive sessions of gains. this occurred despite an uptick in cac 40 of just 0.226% to eur7,443.88, partially offsetting its previous session's drop.

share performance

saint jean groupe closed at eur22.40 last friday, representing no change from its 52-week high of eur26.00 and with its 52-week low standing at eur16.90. at eur0.18, this company's trailing twelve-month earnings per share are relatively modest. this produces an astronomically high price to earnings ratio - 109.44 in fact - meaning investors would have to shell out eur109.44 in order to purchase just one euro of annual earnings.

company's financial status

the return on equity over this same time frame stands at only 0.81%. saint jean groupe saw its highest average intraday variation over the last week at 4.31%, 3.11% over the past month and 2.78% for the last quarter. saint jean groupe's stock dropped today; however, its value still exceeds both its 50-day moving average of eur19.14 and 200-day moving average of eur18.71.

market trends

in fact, today's results demonstrate how far higher its current share price is than its 52-week low, further strengthening an optimistic outlook for saint jean groupe. however, today's traded volume for saint jean groupe was considerably below average compared to its typical volume of 170 shares changing hands each day. this could indicate decreasing investor enthusiasm about investing in this company despite its attractive p/e ratio.

investment considerations

based on these financial indicators, potential investors should carefully assess the return on equity and p/e ratio, taking into account recent share price drops and increased volatility.

more news about saint jean groupe (sabe.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com